Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer: A Randomized Phase 2 Trial (IMPATIENS)

This is a prospective, open-label, single-center, randomized controlled Phase II clinical study aimed at evaluating the efficacy and safety of neoadjuvant imlunestrant combined with abemaciclib guided by the Ki67 index after 2 weeks in patients with ER+/HER2- breast cancer.

Start Date01 Jul 2026

Sponsor / Collaborator

Fudan University

JPRN-jRCTs031260249

/ RecruitingPhase 2

A randomized study of Trastuzumab deruxtecan Against Second-line endocrine Therapy In hormone receptor-positive, HER2-low/ultralow metastatic breast cancer (TRANSITION)

Start Date29 Jun 2026

Sponsor / Collaborator-

NCT07287098

/ RecruitingPhase 2

preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer

This study will include two groups of patients: Cohort 1 and Cohort 2.
Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. Some will take it without ovarian suppression. Researchers will compare the effects in breast cancer cells to those of another medicine called tamoxifen. All patients in this group will be premenopausal women who have a type of early breast cancer called estrogen receptor-positive, HER2-negative. The treatment in this group will last for up to 29 days.
Cohort 2: will help researchers understand how imlunestrant affects the ovaries when it is taken without ovarian suppression. Researchers will compare the effects to those of another medicine called tamoxifen. This group will also include premenopausal women with the same type of breast cancer. The treatment in this group will last for up to 6 months.

Start Date13 May 2026

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with Imlunestrant Tosylate

100 Translational Medicine associated with Imlunestrant Tosylate

100 Patents (Medical) associated with Imlunestrant Tosylate

Literatures (Medical) associated with Imlunestrant Tosylate

01 Apr 2026·ANNALS OF ONCOLOGY

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial

Article

Author: Llombart-Cussac, A ; Lim, E ; Huang, J ; Wang, X A ; Kim, S-B ; Qingyuan, Z ; Carey, L A ; Huang, C ; Casalnuovo, M L ; Bidard, F C ; Jhaveri, K L ; Tokunaga, E ; Saura, C ; Harbeck, N ; Limay, Y ; O'Shaughnessy, J ; Neven, P ; Desai, B ; Watanabe, J ; Curigliano, G ; Cao, S ; Aftimos, P

BACKGROUND:

At the primary progression-free survival (PFS) analysis, the phase III EMBER-3 trial in endocrine therapy-pretreated patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) demonstrated significant PFS benefit with imlunestrant versus standard of care (SOC: fulvestrant or exemestane) in patients with ESR1 mutations (ESR1m) and with imlunestrant-abemaciclib versus imlunestrant in all patients, regardless of ESR1m. In this article, we report updated efficacy from a prespecified interim overall survival (OS) analysis.

PATIENTS AND METHODS:

Patients with ER-positive, HER2-negative ABC previously treated with aromatase inhibitors ± cyclin-dependent kinase 4 and 6 inhibitors were randomly assigned (1 : 1 : 1) to receive imlunestrant, SOC, and imlunestrant-abemaciclib. Primary endpoints were PFS in imlunestrant versus SOC in patients with ESR1m and all patients, and versus imlunestrant-abemaciclib in all concurrently randomized patients. OS was a key secondary endpoint (tested if the corresponding PFS was statistically significant). Due to only two of three PFS endpoints being met, a limited significance level was passed to the OS comparisons. Exploratory endpoints included time to chemotherapy, chemotherapy-free survival, and PFS2.

RESULTS:

A total of 874 patients were randomized (imlunestrant, n = 331; SOC, n = 330; imlunestrant-abemaciclib, n = 213). Median follow-up was 28.5 months; 10.1% of patients remained on treatment (data cut-off: 18 August 2025).In patients with ESR1m, median OS (mOS) was 34.5 months for imlunestrant versus 23.1 months for SOC [hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.43-0.86, P = 0.0043, boundary for significance not reached]. In all patients regardless of ESR1m, mOS was not reached with imlunestrant-abemaciclib versus 34.4 months with imlunestrant (HR 0.82, 95% CI 0.59-1.16, P = 0.2622). Updated PFS demonstrated sustained benefit. Notably, in all patients regardless of ESR1m, the median PFS of imlunestrant-abemaciclib versus imlunestrant was 10.9 versus 5.5 months (HR 0.59, 95% CI 0.47-0.74, nominal P < 0.0001). All prespecified exploratory endpoints favored imlunestrant-based regimens. Safety remains consistent with prior reports.

CONCLUSIONS:

These findings reinforce the clinical benefit of imlunestrant-based regimens as a potential all-oral, chemotherapy-free treatment option for endocrine-pretreated patients with ER-positive, HER2-negative ABC.

01 Apr 2026·ESMO Open

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial

Article

Author: Fairhurst, S ; Karadurmus, N ; Okera, M ; Carey, L A ; Melo, E ; Jhaveri, K L ; Bidard, F-C ; Magallanes-Maciel, M ; Wang, X A ; O'Shaughnessy, J ; Miller, J ; Tokunaga, E ; Harbeck, N ; Saura, C ; Bahadur, S ; Casalnuovo, M L ; Speck, R M ; Kitchen, H ; Zagouri, F ; Curigliano, G ; Kim, S-B ; Aftimos, P ; Pradhan, K ; Macey, J

BACKGROUND:

Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen receptor degrader. In the phase III EMBER-3 trial, conducted in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer, imlunestrant demonstrated a significant progression-free survival benefit compared with standard endocrine therapy (standard of care; fulvestrant or exemestane) in patients harboring ESR1 mutations (ESR1m). Additionally, the combination of imlunestrant and abemaciclib improved outcomes compared with imlunestrant monotherapy, irrespective of ESR1m status. This manuscript reports findings from exploratory analyses of patient-reported outcome (PRO) measures and qualitative interviews evaluating EMBER-3 participants' experiences and treatment preferences.

MATERIALS AND METHODS:

PROs administered were the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and the PRO-Common Terminology Criteria for Adverse Events (CTCAE) items for diarrhea frequency and injection site reactions (for fulvestrant recipients only). Mean changes from baseline in EORTC QLQ-C30 scores were calculated using a longitudinal mixed model for repeated measures; a 10-point change defined as clinically meaningful. PRO-CTCAE analyses were descriptive. Interview transcripts were analyzed using directed content analysis techniques.

RESULTS:

Overall, global health status/quality of life (GHS/QoL) and function were generally maintained over time across treatment arms among the ESR1m population and all patients, with treatment differences favoring imlunestrant versus SOC among the ESR1m population. Fewer GHS/QoL and function deterioration events occurred in the imlunestrant arm (ESR1m and all patients) compared with other treatment arms. Most (72.3%) fulvestrant-treated patients reported injection site reactions at any time. Diarrhea frequency was consistently higher in the combination arm of imlunestrant-abemaciclib.

CONCLUSION:

GHS/QoL and function were maintained across treatment arms, despite a higher incidence of diarrhea in the imlunestrant-abemaciclib group. These PRO findings complement the efficacy and safety results from EMBER-3 and further support the favorable risk-benefit profile of imlunestrant, either as oral monotherapy or in combination with abemaciclib, in patients with advanced breast cancer.

01 Mar 2026·International Journal of Clinical Oncology

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; imlunestrant for breast cancer, tafasitamab for follicular lymphoma, atezolizumab for thymic carcinoma, retifanlimab for anal canal squamous cell carcinoma, and tagraxofusp for blastic plasmacytoid dendritic cell neoplasm

Author: Matsumura, Noriomi

News (Medical) associated with Imlunestrant Tosylate

01 Jul 2026

·www.pharmaceutical-technology.com

Eli Lilly and Innovent agree Verzenios commercialisation deal in China

Verzenios indicated for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer. Credit: Peakstock/Shutterstock.com. Eli Lilly and Company has entered into an agreement with Innovent Biologics for the commercialisation of Verzenios (abemaciclib) in mainland China. Under this agreement, Innovent will handle the marketing, distribution and promotion of the product within the region, while Eli Lilly will continue to manage manufacturing, supply and development. Verzenios is a cyclin-dependent kinase 4 (CDK4) and 6 inhibitor that has received approval in China for several indications related to breast cancer. Originally developed by Eli Lilly, it is approved in the country for use in combination with endocrine therapy as an adjuvant treatment for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. It is also indicated for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer. In these settings, the therapy may be delivered in combination with an aromatase inhibitor, fulvestrant or imlunestrant. Since 2021, Verzenios has been included in China’s National Reimbursement Drug List (NRDL) Class B, making it the first CDK4 and 6 inhibitor covered by national reimbursement. Its renewal in the NRDL for 2025 provides continued coverage for both early and advanced breast cancer indications. Innovent founder, board chairman and CEO Dr Michael Yu said: “Leveraging our established commercial infrastructure and strong market presence in China, we remain focused on addressing critical unmet needs in major oncology indications. Breast cancer, one of the most prevalent and life-threatening malignancies among women, is a strategic priority within Innovent’s oncology portfolio. “Through this commercial collaboration with Lilly on Verzenios (abemaciclib) – backed by its robust clinical efficacy, comprehensive labelled indications and national reimbursement coverage – we are expanding our presence in this area, laying a solid foundation for our pipeline development and market expansion [to] deliver lasting benefits to patients in breast cancer.” Last month, Eli Lilly entered a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide (a LAPS GLP-2 analogue), worldwide, excluding Korea.

30 Jun 2026

·www.prnewswire.com

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios® (abemaciclib) in mainland China: Innovent will be responsible for the importation, marketing, distribution and promotion of Verzenios® (abemaciclib) in mainland China; Lilly will continue to be responsible for manufacturing, supply, and development for the product. Verzenios® (abemaciclib), developed by Lilly, is a CDK4 & 6 inhibitor that has been approved in China for multiple indications, including: (1) Early Breast Cancer: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. (2) Locally Advanced or Metastatic Breast Cancer: a) For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women. In combination with fulvestrant for patients who have experienced disease progression following prior endocrine therapy. b) In combination with imlunestrant: for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer who have previously received endocrine therapy. The product was included in the National Reimbursement Drug List (NRDL) Class B in 2021, becoming the first CDK4 & 6 inhibitor covered by national reimbursement in China. In 2025, it successfully renewed its NRDL listing, achieving full coverage across both early and advanced breast cancer indications. Under the agreement, Innovent will hold sole commercialization rights for Verzenios® (abemaciclib) in mainland China, while Lilly, as the Marketing Authorization Holder (MAH), will continue to be responsible for manufacturing, supply, and ongoing product development. This collaboration combines Innovent's experienced oncology commercialization team and extensive market reach in China with Lilly's expertise in innovative medicine development and lifecycle management, further enhancing access to this important therapy and benefiting more breast cancer patients across the country. Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "We are delighted to further deepen our strategic partnership with Lilly through this eighth collaboration, bringing the number of our partnered, on-market products in China to seven. This also marks the 19th product in Innovent's portfolio. Enhancing patient access to high-quality, innovative medicines has always been at the core of Innovent's mission. Leveraging our established commercial infrastructure and strong market presence in China, we remain focused on addressing critical unmet needs in major oncology indications. Breast cancer, one of the most prevalent and life–threatening malignancies among women, is a strategic priority within Innovent's oncology portfolio. Through this commercial collaboration with Lilly on Verzenios® (abemaciclib) – backed by its robust clinical efficacy, comprehensive labeled indications and national reimbursement coverage – we are expanding our presence in this area, laying a solid foundation for our pipeline development and market expansion deliver lasting benefits to patients in breast cancer." Huzur Devletsah, Lilly Group Vice President and China General Manager, said: "For 150 years, Lilly has remained committed to putting health above all, advancing human health through scientific innovation and expanding access through collaboration. This agreement for Verzenios® (abemaciclib) is an important step in strengthening patient access in China, combining Lilly's global R&D expertise with Innovent's commercialization capabilities in China. Looking ahead, Lilly will continue to advance its oncology efforts in China. Since the beginning of this year, we have secured approvals for one new medicine (with two indications) and two new additional indications for on market products in China, including Inluriyo®, which has become the first and currently only approved precision therapy in China only targeting ESR1-mutated advanced breast cancer, accelerating the introduction of globally innovative therapies and addressing unmet medical needs." About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 19 products in the market. It has 1 asset in NMPA NDA review, 5 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Takeda, Pfizer, Roche, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo), Pirtobrutinib (Jaypirca) and abemaciclib (Verzenios) were developed by Eli Lilly and Company. Disclaimer: Innovent does not recommend any off-label usage. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. Forward-Looking Statements of Innovent Biologics This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. SOURCE Innovent Biologics 21% more press release views with Request a Demo

Drug ApprovalLicense out/inNDA

17 Jun 2026

·allsci.com

Rigel closes USD 70m Veppanu deal with Arvinas and Pfizer

Rigel Pharmaceuticals (Nasdaq: RIGL) has closed its exclusive global license for Veppanu (vepdegestrant), paying USD 70 million upfront to Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) — each receiving USD 35 million — for the first FDA-approved PROTAC in history. The deal, effective June 11, transfers commercialization rights for an approved oral estrogen receptor degrader to the San Francisco-based Rigel, a biotech with no prior presence in breast cancer. Rigel expects to launch Veppanu commercially in August 2026. The closing follows the original agreement announced May 12, 2026, under which Rigel will pay an additional USD 15 million upon completion of manufacturing and development transition activities, contribute up to USD 40 million toward ongoing development activities over four years, and is eligible to pay up to USD 320 million in regulatory and commercial milestones. Arvinas and Pfizer are entitled to tiered royalties ranging from mid-teens to mid-twenties percent on net sales, plus a share of sublicensing revenue Rigel generates outside the US. Vepdegestrant is the first approved PROTAC therapy, designed to degrade rather than simply inhibit the estrogen receptor. FDA approval on May 1, 2026 was based on data from VERITAC-2 (NCT05654623), a global, randomized Phase III trial comparing vepdegestrant to fulvestrant in patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. The deal’s economics are strikingly compressed relative to the asset’s history. When Pfizer originally partnered with Arvinas in July 2021 for vepdegestrant’s co-development, Pfizer paid USD 650 million upfront under a deal worth up to USD 1.4 billion plus a 50/50 profit share. Rigel’s USD 70 million upfront — for a post-approval, global asset — represents roughly a 90% discount from that original payment, highlighting the difference between the economics of an early-stage development partnership and a commercial-stage asset with a defined label. The drug enters an increasingly competitive ESR1-mutated breast cancer market that already includes approved oral estrogen receptor-targeting therapies elacestrant (Orserdu) and imlunestrant (Inluriyo), while AstraZeneca’s camizestrant has an FDA decision pending. Veppanu’s PROTAC mechanism offers theoretical differentiation through complete protein degradation, but no head-to-head clinical data against the approved SERDs have been reported. For Rigel, the transaction is a meaningful step-up in scope. Its prior commercial-stage acquisition — US rights to Gavreto (pralsetinib) from Blueprint Medicines in February 2024 for up to USD 102.5 million in milestones plus tiered royalties of 10%–30% — was US-only. Veppanu is Rigel’s first global license and its first oncology asset outside hematology. Notably, Eli Lilly terminated its USD 960 million ocadusertib collaboration with Rigel in April 2026, weeks before the Veppanu deal was announced, removing Rigel’s largest development partnership and creating both financial and strategic impetus to replace it with a commercial-stage asset. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

100 Deals associated with Imlunestrant Tosylate

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
ER-positive/HER2-negative/ ESR1-mutated breast cancer	United States	Eli Lilly & Co.	25 Sep 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
ER-positive/HER2-negative Breast Cancer	NDA/BLA	Canada	Eli Lilly & Co.	01 Feb 2025
Liver Injury	Phase 1	United States	Eli Lilly & Co.	05 Jul 2022
Advanced breast cancer	Phase 1	United States	Eli Lilly & Co.	10 Dec 2019
Advanced breast cancer	Phase 1	Japan	Eli Lilly & Co.	10 Dec 2019
Advanced breast cancer	Phase 1	Australia	Eli Lilly & Co.	10 Dec 2019
Advanced breast cancer	Phase 1	Belgium	Eli Lilly & Co.	10 Dec 2019
Advanced breast cancer	Phase 1	France	Eli Lilly & Co.	10 Dec 2019
Advanced breast cancer	Phase 1	South Korea	Eli Lilly & Co.	10 Dec 2019
Advanced breast cancer	Phase 1	Spain	Eli Lilly & Co.	10 Dec 2019
Advanced breast cancer	Phase 1	Taiwan Province	Eli Lilly & Co.	10 Dec 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2026	Phase 2/3	Hormone receptor positive HER2 negative breast cancer HR Positive \| HER2 Negative	16	Imlunestrant alone	xpkxqqoafj(apcuwpctse) = fvghofoope dwazojxfla (jbeooqlyaw ) View more	Positive	21 Apr 2026
				Camizestrant 75mg	xpkxqqoafj(wquimhqcww) = ctwbucjsrd nffuodgktr (ilvufexbfo ) View more
EMBER-3 (SABCS2025)	Phase 3	ER-positive/HER2-negative Breast Cancer ESR1 mutations	635	Imlunestrant	jwfgkcnmca(bmilablllu) = qlaxcueuek wdcftgjoan (gogjjfexnl ) View more	Positive	11 Dec 2025
				Standard Endocrine Therapy (SOC ET)	jwfgkcnmca(okaznswpoe) = ojgzmzlqbz pvkblzyfvd (jqkhlwvrmk )
NCT04975308 (EMBER-3, SABCS2025 \| Company_Website \| Pubmed \| Ann Oncol) Manual	Phase 3	ER-positive/HER2-negative Breast Cancer HER2 Negative \| Estrogen receptor positive \| ESR1 Mutation	874	Imlunestrant (pts with ESR1 mutation)	swqvssxliy(vdsaeeaaht) = ewgdgqtmnt rikhaitvra (pcrqfgstjz, 3.9 - 7.4) View more	Positive	09 Dec 2025
				SOC: Fulvestrant or Exemestane (pts with ESR1 mutation)	swqvssxliy(vdsaeeaaht) = wsqvffugbh rikhaitvra (pcrqfgstjz, 3.7 - 5.5) View more
NCT04991766 (CTgov)	Phase 1	-	16	[¹⁴C]-LY3484356 (Part 1: [¹⁴C]-LY3484356)	twsfwdwhkt(cnfvvzpjgp) = cwzedagzlg omljkekutz (oljafthjij, nblpzsghiy - suanfobwnp) View more	-	05 Dec 2025
				[¹⁴C]-LY3484356 (Part 2: LY3484356 + [¹⁴C]-LY3484356)	uwvzvejjrg(amrskwnvzh) = plcnqeevhn bpjksrolgt (cxxardauzk, 32) View more
NCT04647487 (EMBER-2, CTgov)	Phase 1	ER-positive/HER2-negative Breast Cancer	87	LY3484356 (400 mg LY3484356)	jsowltvapd(qaahyhvccs) = ujorsjjmvx dyexwggjdg (xxcicsajuo, sndnnhyelp - ypnvprqhcz) View more	-	12 Nov 2025
				LY3484356 (800 mg LY3484356)	jsowltvapd(qaahyhvccs) = cwfwmvvacx dyexwggjdg (xxcicsajuo, yvwcatxduj - cvyxmmrfuu) View more
NCT05440344 (CTgov)	Phase 1	Liver Injury	27	Imlunestrant (Imlunestrant (Normal Hepatic Function))	rolqlipjtg(gcntqbpqfs) = gvpuffsqed koieljelgh (qwwnstiuic, 56) View more	-	12 Nov 2025
				Imlunestrant (Imlunestrant (Mild Hepatic Impairment))	rolqlipjtg(gcntqbpqfs) = mnjllwsnzs koieljelgh (qwwnstiuic, 47) View more
NCT05509816 (CTgov)	Phase 1	-	20	Midazolam (0.5 mg Midazolam)	nqrbmhpviv(enfgtkylln) = addfdhgvgf ljvfgdswll (paooopigti, 32) View more	-	12 Nov 2025
				Imlunestrant+Midazolam (0.5 mg Midazolam + 400 mg Imlunestrant)	nqrbmhpviv(enfgtkylln) = eyrtspeoxm ljvfgdswll (paooopigti, 41) View more
NCT04975308 (EMBER-3, FDA_CDER) Manual	Phase 3	ER-positive/HER2-negative/ ESR1-mutated breast cancer \| Locally advanced breast cancer \| Metastatic breast cancer	874	INLURIYO	edydunsyov(dvjxvoekhs) = bjomimoiid ipbvghceig (aubnqrmvxw, 3.9 - 7.4) View more	Positive	25 Sep 2025
				Fulvestrant or Exemestane	edydunsyov(dvjxvoekhs) = pbczosywfo ipbvghceig (aubnqrmvxw, 3.7 - 5.5) View more
NCT04975308 (EMBER-3, CTgov)	Phase 3	ER-positive/HER2-negative Breast Cancer	874	Imlunestrant (Arm A: Imlunestrant)	qtuqvssoop(zvtvvlorlk) = coebqkfkzf eszkbahgxw (ntstvgculs, mutebobyqu - yhihfmzrqa) View more	-	11 Jul 2025
				fulvestrant+Exemestane (Arm B: Investigator's Choice of Endocrine Therapy)	qtuqvssoop(zvtvvlorlk) = zbdygpuadv eszkbahgxw (ntstvgculs, oqbsaojqcn - xywqmynbhq) View more
NCT04975308 (EMBER-3, ASCO2025)	Phase 3	Advanced breast cancer	859	Imlunestrant 400 mg QD	kipzvmczby(ijkrkxarba) = 1/0 and 2/0 umzgoopvty (lwalgwbhku ) View more	Positive	30 May 2025
				Standard therapy (fulvestrant or exemestane)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis